| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3878207 | The Journal of Urology | 2008 | 8 Pages |
Abstract
The inhibition of 5α-reductase represents a valid target for prostate cancer risk reduction and treatment strategies. The greater suppression of dihydrotestosterone observed with agents that inhibit each 5α-reductase isoenzyme may translate into enhanced outcomes and studies are under way to test this hypothesis.
Keywords
Reduction by Dutasteride of Prostate Cancer EventsDHTPCPTPSA5αR5α-reductaseADIprostatic intraepithelial neoplasiaProstate specific antigenandrogenstransit amplifyingProstate Cancer Prevention TrialDihydrotestosteroneandrogen response elementProstatic neoplasmsAREBenign prostatic hyperplasiaBPHProstatePINreduceAndrogen Receptor
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Donald J. Tindall, Roger S. Rittmaster,